Proflaxis for Healthcare Professionals Using Hydroxychloroquine Plus Vitamin Combining Vitamins C, D and Zinc During COVID-19 Pandemia: An Observational Study
试验速览
- 阶段
- 不适用
- 入组人数
- 80
- 试验地点
- 1
- 主要终点
- Protection against COVID-19
研究概览
简要总结
Healthcare professionals mainly doctors, nurses and their first degree relatives (spouse, father, mother, sister, brother, child) who have been started hydroxychloroquine(plaquenil) 200mg single dose repeated every three weeks plus vitaminC including zinc once a day were included in the study. Study has conducted on 20th of march. Main purpose of the study was to cover participants those who are facing or treating COVID19 infected patients in Ankara.
详细描述
Healthcare professionals mainly doctors, nurses and their first degree relatives (spouse, father, mother, sister, brother, child) who have been started hydroxychloroquine(plaquenil) 200mg single dose repeated every three weeks plus vitaminC including zinc once a day were included in the study. Study has conducted on 20th of march. Main purpose of the study was to cover participants those who are facing or treating COVID19 infected patients.PArticipants, age, sex, BMI, smoking history, comorbid disease were also registered.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Prospective
入排标准
- 年龄范围
- 20 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •person who are working as health professional with contact to known COVID positive case
- •Their first degree relatives (child, spouse or parents)
- •must be able to swallow tablets
排除标准
- •Already using plaquenil for other reasons (RA etc)
- •person with the diagnosis of COVID infection
- •Person with the condition may cause complications with this medication (severe CVD, av block, already has ophtalmological complications, organ failure of any degree etc).
- •Documented allergic history to chloroquine;
- •Documented history of hematological system diseases;
- •Documented history of chronic liver and kidney diseases;
- •Documented history of cardiac arrhythmia or chronic heart diseases;
- •Documented history of retina or hearing dysfunction;
- •Documented history of mental illnesses;
- •Use of digitalis due to the previous disease.
研究组 & 干预措施
Hydroxychloroquine
Subjects with prophylaxis
干预措施: Plaquenil 200Mg Tablet (Drug)
结局指标
主要结局
Protection against COVID-19
时间窗: 4 months
persons who took this medication should not have an infection
次要结局
未报告次要终点
研究者
Mehmet Mahir Ozmen
Professor of Surgery, Department of Surgery
Istinye University